Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic use in paediatric liver transplant recipients at risk of renal dysfunction
2005-001830-34Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate sodium in liver transplant and chronic kidney disease (CKD) (2 arms), sponsored by King's College Hospital. Primary endpoints: Renal dysfunction (GFR) at one year, Incidence of rejection at one year and 2 more. Started Apr 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
liver transplantchronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-001830-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001830-34.